ESAR - European Surveillance of Antibiotic Resistance
All in-patients; infection and discipline known; 1999 and 2000
Therapy

Type of Infection: Skin/ soft Tissue
  Total Type of therapy
missing Prophylaxis Treatment
N % N % N % N %
Substance 52 18.71 22 7.91 3 1.08 27 9.71
3rd gen. cephalosporins
aminopenicillin + -lact.inh. 43 15.47 12 4.32 - - 31 11.15
quinolones 31 11.15 11 3.96 1 0.36 19 6.83
aminoglycosides 23 8.27 14 5.04 2 0.72 7 2.52
polypeptides 20 7.19 1 0.36 4 1.44 15 5.40
methylpenicillin 17 6.12 4 1.44 - - 13 4.68
2nd gen. cephalosporins 15 5.40 3 1.08 3 1.08 9 3.24
penicillins 13 4.68 3 1.08 - - 10 3.60
macrolides 11 3.96 1 0.36 - - 10 3.60
glycopeptide 9 3.24 1 0.36 - - 8 2.88
acylaminopenicillin + -lact.inh. 7 2.52 4 1.44 1 0.36 2 0.72
sulfonamides 6 2.16 3 1.08 - - 3 1.08
aminopenicillin 6 2.16 2 0.72 1 0.36 3 1.08
1st gen. cephalosporins 4 1.44 - - - - 4 1.44
carbapenems 4 1.44 - - - - 4 1.44
lincosamides 4 1.44 2 0.72 - - 2 0.72
Fusidic acid 2 0.72 - - - - 2 0.72
4th gen. cephalosporins 2 0.72 2 0.72 - - - -
acylaminopenicillin 2 0.72 2 0.72 - - - -
cephalosporin 2 0.72 2 0.72 - - - -
misc. antibiotics 1 0.36 - - - - 1 0.36
antituberculosis agents 1 0.36 - - - - 1 0.36
antifungals 1 0.36 - - 1 0.36 - -
vaginal preparations 1 0.36 - - - - 1 0.36
topical antiinfectives 1 0.36 1 0.36 - - - -
Total 278 100.00 90 32.37 16 5.76 172 61.87

ESBiC Study Center